|
Q1 FY2027
As of Jun 30, 2026
|
Q4 FY2026
As of Mar 31, 2026
|
Q3 FY2026
As of Dec 31, 2025
|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jun 30, 2025
|
Q4 FY2025
As of Mar 31, 2025
|
Q3 FY2025
As of Dec 31, 2024
|
Q2 FY2025
As of Sep 30, 2024
|
Q1 FY2025
As of Jun 30, 2024
|
Q4 FY2024
As of Mar 31, 2024
|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable—trade, net | ||||||||||||||||||||
| Accounts receivable—other, net | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Financing receivables-net, current | ||||||||||||||||||||
| Financing receivables—net, current | ||||||||||||||||||||
| Deferred costs | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Current assets of discontinued operations | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Financing receivables and operating leases—net | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Property, equipment, and other assets—net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets—net | ||||||||||||||||||||
| Non-current assets of discontinued operations | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accounts payable—floor plan | ||||||||||||||||||||
| Salaries and commissions payable | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Non-recourse notes payable—current | ||||||||||||||||||||
| Recourse | ||||||||||||||||||||
| Non-recourse | ||||||||||||||||||||
| Total non-recourse notes payable—current | ||||||||||||||||||||
| Contract liabilities | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Current liabilities of discontinued operations | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-recourse notes payable—long-term | ||||||||||||||||||||
| Non-recourse | ||||||||||||||||||||
| Total non-recourse notes payable—long-term | ||||||||||||||||||||
| Deferred tax liability—long-term | ||||||||||||||||||||
| Deferred revenue—long-term | ||||||||||||||||||||
| Contract liabilities—long-term | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Non-current liabilities of discontinued operations | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Preferred stock, $0.01 per share par value; 2,000 shares authorized; none outstanding | ||||||||||||||||||||
| Common stock, $0.01 per share par value; 50,000 shares authorized; 27,920 shares issued and 26,149 outstanding at June 30, 2026, and 27,765 shares issued and 26,299 outstanding at March 31, 2026 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock, at cost, 1,466 shares at March 31, 2026, and 1,056 shares at March 31, 2025 | ||||||||||||||||||||
| Treasury stock, at cost, 1,771 shares at June 30, 2026, and 1,466 shares at March 31, 2026 | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive income—foreign currency translation adjustment | ||||||||||||||||||||
| Total Stockholders’ Equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
Loading...
